
News|Videos|June 8, 2018
Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC
Author(s)Apar Kishor Ganti, MD, MS
In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.
Advertisement
In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Pembrolizumab/EV Combo in Muscle Invasive Bladder Cancer
2
FDA Approves Subcutaneous Isatuximab in Multiple Myeloma
3
HARMONi-6: Evaluating the Safety and Generalizability of Ivonescimab in NSCLC
4
EMA’s Review of Daraxonrasib in PDAC Accelerated Under Phased Review Process
5















































































